Why is Glaxosmi. Pharma falling/rising?

As of 06-Nov, Glaxosmithkline Pharmaceuticals Ltd is experiencing a decline in its stock price, currently at 2,599.75, reflecting a decrease of 61.75 points or 2.32%. The stock has underperformed its sector by 1.55% today and has been on a downward trend for the last two days, accumulating a total loss of 3.19% during this period. Additionally, the stock is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend. Despite a high management efficiency with a return on equity (ROE) of 42.32% and a low debt-to-equity ratio, the company faces challenges such as poor long-term growth, with net sales growing at an annual rate of only 3.92% over the last five years, and a high valuation compared to its peers, which may be contributing to the stock's recent decline.
In the broader market context, Glaxosmithkline's short-term performance has been relatively better than the benchmark Sensex, with a 1-week return of -0.75% compared to the Sensex's -1.30%. However, the stock has underperformed over the past month, with a decline of 4.97% while the Sensex has gained 1.86%. The company's flat results reported in September and a high price-to-book value ratio of 22.6 suggest that investors may be cautious, leading to the stock's current downward movement despite its recent profitability increase of 25.8%. Overall, the combination of high valuation concerns and stagnant growth prospects appears to be weighing on investor sentiment, contributing to the stock's decline.